CS
BOLT icon

Credit Suisse’s Bolt Biotherapeutics BOLT Stock Holding History

Credit Suisse’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4050
2022
Q2 		$0 Sell
1
-611
-100% -$23.7K ﹤0.01% 3946
2022
Q1 		$34K Buy
612
+79
+15% +$5.32K ﹤0.01% 3529
2021
Q4 		$52K Buy
+533
New +$101K ﹤0.01% 4419

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Credit Suisse's BOLT Position: Q3 2022 in Review

Credit Suisse sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in BOLT in Q4 2021 and held it in 3 quarters. The position peaked at $52K in Q4 2021. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • Credit Suisse reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Bolt Biotherapeutics share in Q3 2022.
  • Credit Suisse first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Credit Suisse's Bolt Biotherapeutics position peaked at $52K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.